MOLECULAR GENETIC CHARACTERISTICS OF MYCOBACTERIUM TUBERCULOSIS ISOLATES CIRCULATING IN ASTANA
Main Article Content
Authors
D. Auganova
National Center for Biotechnology, 13/5 Korgalzhyn Highway, Astana, 010000, Kazakhstan
S. Atavliyeva
National Center for Biotechnology, 13/5 Korgalzhyn Highway, Astana, 010000, Kazakhstan
A. Amirgazin
National Center for Biotechnology, 13/5 Korgalzhyn Highway, Astana, 010000, Kazakhstan
A. Akisheva
City Center for Phthisiopulmonology of the Akimat of Astana, A1 Street, Building 5, 010000, Astana, Kazakhstan
S. Abeldenov
National Center for Biotechnology, 13/5 Korgalzhyn Highway, Astana, 010000, Kazakhstan
A. Tsepke
City Center for Phthisiopulmonology of the Akimat of Astana, A1 Street, Building 5, 010000, Astana, Kazakhstan
P. Tarlykov
National Center for Biotechnology, 13/5 Korgalzhyn Highway, Astana, 010000, Kazakhstan
Abstract
According to the World Health Organization, Kazakhstan takes a leading position in the number of cases of multidrug-resistant tuberculosis. This work is aimed at studying clinical isolates of Mycobacterium tuberculosis circulating in Astana in 2021–2022. Among 198 M. tuberculosis isolates collected, 175 (88.38%) belonged to the L2/Beijing family, and the remaining 23 samples (11.62%) belonged to the L4 family. During the research used genotyping aimed at determining the genetic family of M. tuberculosis, as well as whole-genome sequencing of selected 24 L2/Beijing isolates with their subsequent bioinformatics analysis. According to the analysis results, 62.5% of isolates were assigned to the Central Asia Outbreak genotype. The remaining genotypes were represented by Central Asia (20.8%), B0/W148 (12.5%) and Clade A (4.2%). Besides that, phenotypic and genotypic characterization of the resistance of selected isolates to anti-tuberculosis drugs was carried out. One of the possible reasons for the spread of resistant forms of tuberculosis in the country is the predominance of the Central Asia Outbreak genetic cluster associated with MDR-TB.
Keywords
Mycobacterium tuberculosis, drug-resistance, rifampicin, isoniazid
Article Details
References
WHO. Global Tuberculosis Reports 2023 // World Health Organization. – 2023.
United Nations. Sustainable Development Goals Report 2022 // United Nations. – 2022.
Gordon S. V., Parish T. Microbe profile: Mycobacterium tuberculosis: Humanity’s deadly microbial foe // Microbiology. – 2018. – Vol. 164. – №. 4. – P. 437–439.
Cole S., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., ... & Barrell B. G. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence // Nature. – 1998. – Vol. 393. – №. 6707. – P. 537–544.
WHO. Global Tuberculosis Reports 2021 // World Health Organization. – 2021.
WHO. Global Tuberculosis Reports 2020 // World Health Organization. – 2020.
WHO. WHO consolidated guidelines on tuberculosis // World Health Organization Press. – 2022.
Comas I., Coscolla M., Luo T., Borrell S., Holt K. E., Kato-Maeda M., ... & Gagneux S. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans // Nature Genetics. – 2013. – Vol. 45. – №. 10. – P. 1176–1182.
Gagneux S. Ecology and evolution of Mycobacterium tuberculosis // Nature Reviews Microbiology. Nature Publishing Group. – 2018. – Vol. 16. – №. 4. – P. 202–213.
Luo T., Comas I., Luo D., Lu B., Wu J., Wei L., ... & Gao Q. Southern East Asian origin and coexpansion of Mycobacterium tuberculosis Beijing family with Han Chinese // Proceedings of the National Academy Sciences. – 2015. – Vol. 112. – №. 26. – P. 8136–8141.
Mokrousov I., Narvskaya O., Otten T., Vyazovaya A., Limeschenko E., Steklova L., Vyshnevskyi B. Phylogenetic reconstruction within Mycobacterium tuberculosis Beijing genotype in northwestern Russia // Research in Microbiology. – 2002. – Vol. 153. – №. 10. – P. 629–637.
Coscolla M., Gagneux S. Consequences of genomic diversity in Mycobacterium tuberculosis// Seminars in Immunology. Academic Press. – 2014. – Vol. 26. – №. 6. – P. 431–444.
Mokrousov I., Ly H. M., Otten T., Lan N. N., Vyshnevskyi B., Hoffner S., Narvskaya O. Origin and primary dispersal of the Mycobacterium tuberculosis Beijing genotype: clues from human phylogeography // Genome Research. – 2005. – Vol.15. – №. 10. – P. 1357–1364.
Merker M., Blin C., Mona S., Duforet-Frebourg N., Lecher S., Willery E., ... & Wirth T. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage // Nature Genetics. Nature Publishing Group. – 2015. – Vol. 47. – №. 3. – P. 242–249.
Ma P., Luo T., Ge L., Chen Z., Wang X., Zhao R., ... & Bao L. Compensatory effects of M. tuberculosis rpoB mutations outside the rifampicin resistance-determining region // Emerging Microbes & Infections. – 2021. – Vol.10. – №. 1. – P. 743-752.
Merker M., Barbier M., Cox H., Rasigade J. P., Feuerriegel S., Kohl T. A., ... & Niemann S. Compensatory evolution drives multidrug-resistant tuberculosis in Central Asia // Elife. – 2018. – Vol. 7. – P. 1–31.
WHO. Global Tuberculosis Reports 2018 // World Health Organization. – 2018.
Nahid P., Mase S. R., Migliori G. B., Sotgiu G., Bothamley G. H., Brozek J. L., ... & Seaworth B. Treatment of drug-resistant tuberculosis an official ATS/CDC/ERS/IDSA clinical practice guideline // American Journal of Respiratory and Critical Care Medicine. – 2019. – Vol. 200. – №. 10. – P. 93–142.
Millard J., Ugarte-Gil C., Moore D. A. J. Multidrug resistant tuberculosis // BMJ. – 2015. – Vol. 350. – P. 1–6.
Kohl T. A., Utpatel C., Schleusener V., De Filippo M. R., Beckert P., Cirillo D. M., Niemann S. MTBseq: a comprehensive pipeline for whole genome sequence analysis of Mycobacterium tuberculosis complex isolates // PeerJ. PeerJ Inc. – 2018. – Vol. 6. – P. 1-13.
Auganova D., Atavliyeva S., Amirgazin A., Akisheva A., Tsepke A., Tarlykov P. Genomic Characterization of Drug-Resistant Mycobacterium tuberculosis L2/Beijing Isolates from Astana, Kazakhstan // Antibiotics. – 2023. – Vol. 12. – №. 10. – P. 1–17.